Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

8.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
8.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

8.2K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chimeric CD3ζ chains containing CD28 signalling motifs enhance antigen-specific IL-2 production and expansion of human TCR-engineered T cells <i>in vitro</i>.

Immunotherapy advances·2026
Same author

Exploiting TCR Repertoire Analysis to Select Therapeutic TCRs for Cancer Immunotherapy.

Cells·2025
Same author

Editor's Note: Detection of Wilms' Tumor Antigen-Specific CTL in Tumor-Draining Lymph Nodes of Patients with Early Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024
Same author

Exploitation of CD3ζ to enhance TCR expression levels and antigen-specific T cell function.

Frontiers in immunology·2024
Same author

Targeted Therapy of Multiple Sclerosis: A Case for Antigen-Specific Tregs.

Cells·2024
Same author

Synthetic Cell-Based Immunotherapies for Neurologic Diseases.

Neurology(R) neuroimmunology & neuroinflammation·2023

Related Experiment Video

Updated: Apr 5, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.1K

Engineered T cells can fight malignant T cells.

Hans J Stauss1

  • 1UNIVERSITY COLLEGE LONDON.

Blood
|August 22, 2015
PubMed
Summary

Genetically engineered T cells targeting the CD5 antigen selectively eliminate T-lymphoma cells while sparing normal T cells. This targeted approach offers potential for specific cancer therapies.

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • T-cell lymphoma is a type of cancer affecting T lymphocytes.
  • The CD5 antigen is expressed on both malignant T cells in T-cell lymphoma and normal T cells.
  • Developing targeted therapies that distinguish between cancerous and normal T cells is a significant challenge.

Purpose of the Study:

  • To engineer T cells with specificity for the CD5 lineage marker.
  • To evaluate the selective killing of T-lymphoma cells by these engineered T cells.
  • To assess the safety of this approach regarding normal T cell populations.

Main Methods:

  • Genetic engineering of T cells to express chimeric antigen receptors (CARs) or T cell receptors (TCRs) targeting CD5.
  • In vitro assays to assess the cytotoxic activity of engineered T cells against T-lymphoma cell lines and normal T cells.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.6K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.5K

Related Experiment Videos

Last Updated: Apr 5, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.1K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.6K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.5K
  • Analysis of antigen expression levels on target cells.

    • Main Results:

    • Engineered T cells demonstrated potent and selective killing of T-lymphoma cells expressing CD5.
    • Normal T cells, also expressing CD5, were largely spared from T cell-mediated killing.
    • The differential killing suggests a mechanism beyond simple CD5 expression, potentially related to antigen density or co-receptor modulation.

    Conclusions:

    • Genetically engineered T cells targeting CD5 can effectively and selectively eliminate T-lymphoma cells.
    • This strategy holds promise for developing novel immunotherapies for T-cell malignancies.
    • Further research is warranted to optimize this approach for clinical application.